Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets

Computer modeling shows niacin a key to therapy for covid via enhancing the immune system, inhibiting inflammation and regulating cellular microenvironment.

Overview

This 2021 network pharmacology study (Briefings in Bioinformatics) used computational approaches to identify molecular targets shared between niacin’s known pharmacological actions and COVID-19 pathophysiology. Network pharmacology combines protein-protein interaction networks, drug-target databases, and gene ontology enrichment to systematically identify mechanistic overlaps — rather than testing niacin in patients directly.

The study identified a set of intersection genes that niacin modulates and that are also implicated in COVID-19’s disease mechanisms, suggesting potential therapeutic relevance.

Approach and Key Findings

Network pharmacology is a bioinformatics method, not a clinical trial. The researchers built interaction networks for niacin’s known molecular targets (from drug databases) and for COVID-19 disease genes (from literature and pathway databases), then identified the overlap. This overlap represents the molecular space where niacin could theoretically influence COVID-19 pathophysiology.

Three primary mechanisms emerged from the intersection:

1. Immune enhancement. Key immune-regulating genes appeared in the overlap, including genes involved in T cell activation and innate immune signaling. Niacin has documented immunomodulatory effects — both anti-inflammatory (via GPR109A on macrophages and neutrophils) and immune-supporting (via NAD+ repletion for immune cell function).

2. Inflammation inhibition. Genes related to cytokine signaling — particularly pathways relevant to the cytokine storm mechanism in severe COVID-19 — appeared in the intersection. Niacin’s activation of GPR109A suppresses NF-κB-driven pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) in macrophages, which are central mediators of COVID-19 hyperinflammation.

3. Cellular microenvironment regulation. The analysis identified genes involved in oxidative stress response, cellular senescence, and metabolic adaptation — all disrupted by SARS-CoV-2 infection and all influenced by NAD+ availability and niacin’s effects on cellular metabolism.

Why NAD+ Connects Niacin and COVID-19

COVID-19 infection disrupts NAD+ metabolism. SARS-CoV-2 infection activates PARP enzymes (poly-ADP-ribose polymerases), which consume NAD+ as part of the cellular stress and DNA damage response. PARP hyperactivation during severe infection can deplete cellular NAD+ reserves, impairing mitochondrial function, immune cell activity, and the sirtuin-dependent epigenetic responses needed to control viral replication.

A companion study in this directory (Coronavirus infection and PARP expression dysregulate the NAD metabolome: an actionable component of innate immunity) documents this PARP-NAD+ depletion mechanism directly in COVID-19 patients. Niacin, as the primary driver of NAD+ synthesis via the Preiss-Handler pathway, can replenish NAD+ faster than NR or NMN in some contexts, potentially restoring immune cell function during active infection.

Limitations

Network pharmacology identifies plausible mechanisms — it does not establish clinical efficacy. Computational target identification has high false positive rates, and intersection genes may not represent actionable drug targets even when mechanistically coherent. This study should be interpreted as hypothesis-generating, identifying a molecular rationale for further clinical investigation of niacin in COVID-19, not as evidence that niacin treats COVID-19.

No randomized controlled trials specifically testing niacin for COVID-19 treatment have published definitive results as of this writing.

Relevance to the Niacin Literature

For researchers, this study matters because it situates niacin within the COVID-19 mechanism landscape using a systematic approach. The three mechanisms it identifies — immune enhancement, anti-inflammatory activity, and NAD+ repletion — are supported by mechanistic evidence from other niacin studies. The computational overlap is not surprising given niacin’s documented anti-inflammatory effects via GPR109A and its role as a NAD+ precursor, but having those connections mapped against the COVID-19 disease network is useful for researchers exploring nutritional or pharmacological NAD+ support in infectious disease contexts.